Last reviewed · How we verify
atazanavir/tenofovir/emtricitabine
This is a fixed-dose combination of three antiretroviral drugs that work together to inhibit HIV replication through different mechanisms: atazanavir blocks protease, while tenofovir and emtricitabine inhibit reverse transcriptase.
This is a fixed-dose combination of three antiretroviral drugs that work together to inhibit HIV replication through different mechanisms: atazanavir blocks protease, while tenofovir and emtricitabine inhibit reverse transcriptase. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy.
At a glance
| Generic name | atazanavir/tenofovir/emtricitabine |
|---|---|
| Also known as | Truvada |
| Sponsor | Community Research Initiative of New England |
| Drug class | Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atazanavir is a protease inhibitor that prevents HIV protease from cleaving viral polyproteins, blocking the maturation of infectious viral particles. Tenofovir (a nucleotide reverse transcriptase inhibitor) and emtricitabine (a nucleoside reverse transcriptase inhibitor) both inhibit reverse transcriptase, the enzyme HIV uses to convert its RNA genome into DNA for integration into host cells. The combination provides synergistic suppression of viral replication.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in combination antiretroviral therapy
Common side effects
- Nausea
- Diarrhea
- Headache
- Hyperbilirubinemia
- Renal impairment (tenofovir-related)
- Lactic acidosis (rare)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (PHASE4)
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |